New MHRA chief executive named
pharmafile | July 5, 2013 | Appointment | Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | MHRA, ian hudson
The Department of Health has announced the appointment of Dr Ian Hudson as chief executive of the Medicines and Healthcare Products Regulatory Agency (MHRA).
Hudson is currently the MHRA’s Licensing director, responsible for the majority of medicines licensing activities. He is the UK delegate to the Committee on Human Medicinal Products (CHMP) at the European Medicines Agency and has been its vice-chairman since October 2012. He will take up the post in September when Sir Kent Woods steps down after ten years with the agency.
Lord Howe, Health Minister said: “I am delighted to welcome Dr Hudson to his new role. The MHRA carries out vital work to protect the health and well-being of people by ensuring medicines and medical devices work and are acceptably safe.
“Dr Hudson is used to working to the highest possible standards and maintaining the very toughest scrutiny over a fast-moving industry and I am confident he will find this role a deeply rewarding challenge.”
Hudson added: “I’m delighted to be appointed to the role of chief executive. The MHRA plays a critical role in ensuring that medicines and medical devices help people and are acceptably safe; we support research and development; and protect and promote the health of millions of people through our activities.
“Sir Kent has led the MHRA very effectively and has developed it into one of the leading medicines and medical devices regulators in the world. I am proud to have been selected to succeed him in the autumn.”
Related Content
IMed Consultancy releases white paper on Digital Mental Health Technologies
IMed Consultancy, a consultancy and service provider for the medical and health technology sector, has …
Dual immunotherapy for bowel cancer now available under NHS
Dual immunotherapy, a combination of Opdivo (nivolumab) and Yervoy (ipilimumab), has been granted extension in …
MHRA approve new treatment combo for transplant-ineligible multiple myeloma patients
The Medicine and Healthcare products Regulatory Agency (MHRA) has approved quadruplet therapy, SARCLISA (isatuximab) in …
